Unknown

Dataset Information

0

Efficacy and safety of dimethyl fumarate in treatment-naive Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study.


ABSTRACT: Background:The use of dimethyl fumarate has not been reported in treatment-naïve Japanese patients with relapsing-remitting multiple sclerosis. Objectives:The purpose of this study was to evaluate the efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with relapsing-remitting multiple sclerosis. Methods:APEX was a phase 3, multinational trial, which consisted of a 24-week, randomized (1:1), double-blind study where patients received dimethyl fumarate 240 mg or placebo twice daily, followed by an open-label extension where all patients received dimethyl fumarate 240 mg. The primary endpoints were the total number of new gadolinium-enhancing (Gd+) lesions in Weeks 12-24 (Part I) and long-term safety (Part II). This post-hoc subgroup analysis evaluated the efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with relapsing-remitting multiple sclerosis (n=52) up to Week 72 (24 weeks Part I and 48 weeks Part II). Results:Dimethyl fumarate reduced the mean total number of new gadolinium-enhancing lesions at Weeks 12-24 by 94% versus placebo; the number of patients who had a relapse over 24 weeks was reduced by 72%. Adverse events leading to discontinuation of the study drug were reported in 9% of patients receiving placebo/dimethyl fumarate and 4% of patients in dimethyl fumarate/dimethyl fumarate. Conclusions:Dimethyl fumarate demonstrated sustained efficacy and acceptable tolerability in treatment-naïve Japanese patients with relapsing-remitting multiple sclerosis for 72 weeks.

SUBMITTER: Mori M 

PROVIDER: S-EPMC6558550 | biostudies-literature | 2019 Apr-Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study.

Mori Masahiro M   Ohashi Takashi T   Onizuka Yasuhiro Y   Hiramatsu Katsutoshi K   Hase Masakazu M   Yun Jang J   Matta André A   Torii Shinichi S  

Multiple sclerosis journal - experimental, translational and clinical 20190401 2


<h4>Background</h4>The use of dimethyl fumarate has not been reported in treatment-naïve Japanese patients with relapsing-remitting multiple sclerosis.<h4>Objectives</h4>The purpose of this study was to evaluate the efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with relapsing-remitting multiple sclerosis.<h4>Methods</h4>APEX was a phase 3, multinational trial, which consisted of a 24-week, randomized (1:1), double-blind study where patients received dimethyl fumar  ...[more]

Similar Datasets

| S-EPMC6669851 | biostudies-literature
| S-EPMC7812971 | biostudies-literature
| S-EPMC8108088 | biostudies-literature
| S-EPMC3663606 | biostudies-other
| S-EPMC8310468 | biostudies-literature
| S-EPMC4215289 | biostudies-literature
2019-07-31 | GSE130494 | GEO
| S-EPMC5418934 | biostudies-literature
| S-EPMC7604551 | biostudies-literature
2019-07-31 | GSE130491 | GEO